Stock listing
NASDAQ:MGTX MeiraGTx Holdings plc Stock
Home listing (NASDAQ) of MeiraGTx Holdings plc
Follow MeiraGTx Holdings plc into a list and get an email when it puts out news.
Share price · NASDAQ:MGTX
$7.98 USD -0.34 (-4.1%)
Close on Nov 20, 2026
- Day range
- $7.81 – $8.23 USDNov 20, 2026
- Volume
- 1.01M sharesNov 20, 2026
- Market cap
- $766.4M USDAt the close on Nov 20, 2026 · price × 96.04M shares outstanding
- 52-week range
- $6.62 – $15.35 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $9.34M USDMedian day 755,900 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:MGTX · Home | $7.98 USD | -0.34 (-4.1%) | 1,013,977 | $7.97 | $8.23 | $7.81 | $8.32 | Close on Nov 20, 2026 |
| Frankfurt:328 | €7.15 EUR | -0.25 (-3.4%) | — | €7.30 | €7.30 | €7.15 | €7.40 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:MGTX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $7.98 | -0.34 | -4.1% | $7.97 | $8.23 | $7.81 | 1,013,977 | |
| $8.32 | -0.14 | -1.7% | $8.40 | $8.64 | $8.31 | 584,565 | |
| $8.46 | -0.28 | -3.2% | $8.70 | $8.70 | $8.251 | 825,035 | |
| $8.74 | -0.44 | -4.8% | $9.15 | $9.26 | $8.70 | 706,057 | |
| $9.18 | +0.39 | +4.4% | $8.80 | $9.28 | $8.60 | 731,921 | |
| $8.79 | -0.89 | -9.2% | $9.13 | $9.39 | $8.77 | 1,362,621 | |
| $9.68 | +0.06 | +0.6% | $9.70 | $9.76 | $9.53 | 455,889 | |
| $9.62 | +0.13 | +1.4% | $9.30 | $9.70 | $9.30 | 774,741 | |
| $9.49 | +0.49 | +5.4% | $9.13 | $9.54 | $8.95 | 544,741 | |
| $9.00 | +0.49 | +5.8% | $8.44 | $9.12 | $8.44 | 703,329 | |
| $8.51 | -0.91 | -9.7% | $9.325 | $9.38 | $8.47 | 686,674 | |
| $9.42 | -0.10 | -1.1% | $9.81 | $9.92 | $9.39 | 597,709 | |
| $9.52 | +0.20 | +2.1% | $9.36 | $9.52 | $9.31 | 393,365 | |
| $9.32 | -0.17 | -1.8% | $9.50 | $9.521 | $9.20 | 580,103 | |
| $9.49 | -0.215 | -2.2% | $9.65 | $9.70 | $9.30 | 452,176 | |
| $9.705 | -0.045 | -0.5% | $9.79 | $9.895 | $9.54 | 499,163 | |
| $9.75 | +0.35 | +3.7% | $9.28 | $9.765 | $9.15 | 633,144 | |
| $9.40 | +0.22 | +2.4% | $9.20 | $9.58 | $9.11 | 722,942 | |
| $9.18 | -0.03 | -0.3% | $9.24 | $9.33 | $9.05 | 648,655 | |
| $9.21 | -0.56 | -5.7% | $9.70 | $9.72 | $9.08 | 595,500 | |
| $9.77 | -0.09 | -0.9% | $9.80 | $10.06 | $9.67 | 471,900 | |
| $9.86 | -0.11 | -1.1% | $9.97 | $10.23 | $9.835 | 635,600 | |
| $9.97 | +0.52 | +5.5% | $9.45 | $10.11 | $9.405 | 755,900 | |
| $9.45 | +0.17 | +1.8% | $9.48 | $9.73 | $9.29 | 759,500 | |
| $9.28 | -0.61 | -6.2% | $9.89 | $9.89 | $9.245 | 666,400 | |
| $9.89 | +0.48 | +5.1% | $9.42 | $9.93 | $9.38 | 836,400 | |
| $9.41 | -0.53 | -5.3% | $9.82 | $10.01 | $9.36 | 1,104,100 | |
| $9.94 | -0.44 | -4.2% | $10.26 | $10.40 | $9.86 | 1,122,100 | |
| $10.38 | -0.31 | -2.9% | $10.69 | $10.76 | $10.32 | 506,500 | |
| $10.69 | +0.19 | +1.8% | $10.52 | $10.99 | $10.48 | 523,400 | |
| $10.50 | -0.32 | -3.0% | $10.70 | $10.72 | $10.36 | 830,400 | |
| $10.82 | +0.22 | +2.1% | $10.50 | $11.01 | $10.32 | 2,310,000 | |
| $10.60 | -0.32 | -2.9% | $10.93 | $10.95 | $10.53 | 944,400 | |
| $10.92 | +0.13 | +1.2% | $10.77 | $11.03 | $10.59 | 941,600 | |
| $10.79 | +0.13 | +1.2% | $10.75 | $11.00 | $10.66 | 820,000 | |
| $10.66 | -0.34 | -3.1% | $11.36 | $11.36 | $10.54 | 1,066,000 | |
| $11.00 | -0.13 | -1.2% | $11.19 | $11.60 | $10.97 | 1,423,800 | |
| $11.13 | +0.02 | +0.2% | $11.02 | $11.17 | $10.87 | 875,900 | |
| $11.11 | +0.20 | +1.8% | $10.79 | $11.27 | $10.59 | 930,000 | |
| $10.91 | -0.14 | -1.3% | $10.90 | $11.28 | $10.68 | 1,555,600 | |
| $11.05 | -0.70 | -6.0% | $11.42 | $11.56 | $11.00 | 1,605,300 | |
| $11.75 | -0.60 | -4.9% | $12.26 | $12.50 | $11.46 | 1,419,200 | |
| $12.35 | -0.73 | -5.6% | $13.16 | $13.24 | $12.18 | 1,439,300 | |
| $13.08 | -0.17 | -1.3% | $13.47 | $13.47 | $12.80 | 1,286,200 | |
| $13.25 | +0.20 | +1.5% | $12.92 | $13.34 | $12.92 | 941,200 | |
| $13.05 | +0.29 | +2.3% | $13.21 | $13.34 | $12.91 | 953,000 | |
| $12.76 | 0.00 | 0.0% | $12.79 | $12.95 | $12.63 | 917,300 | |
| $12.76 | -0.12 | -0.9% | $12.88 | $12.89 | $12.50 | 1,025,600 | |
| $12.88 | +0.09 | +0.7% | $12.81 | $13.22 | $12.76 | 492,300 | |
| $12.79 | -0.06 | -0.5% | $13.04 | $13.14 | $12.75 | 459,500 | |
| $12.85 | -0.41 | -3.1% | $13.02 | $13.16 | $12.65 | 715,200 | |
| $13.26 | -0.27 | -2.0% | $13.40 | $13.76 | $13.25 | 534,400 | |
| $13.53 | -0.36 | -2.6% | $13.54 | $13.72 | $13.22 | 611,400 | |
| $13.89 | -0.08 | -0.6% | $13.70 | $14.05 | $13.60 | 531,100 | |
| $13.97 | -0.09 | -0.6% | $14.01 | $14.15 | $13.76 | 824,100 | |
| $14.06 | -0.13 | -0.9% | $14.48 | $14.73 | $13.72 | 629,400 | |
| $14.19 | +0.38 | +2.8% | $13.66 | $14.60 | $13.66 | 880,400 | |
| $13.81 | -0.01 | -0.1% | $13.90 | $14.14 | $13.39 | 715,700 | |
| $13.82 | -0.32 | -2.3% | $13.93 | $14.09 | $13.65 | 914,200 | |
| $14.14 | -0.42 | -2.9% | $14.46 | $14.58 | $14.12 | 1,013,600 | |
| $14.56 | -0.36 | -2.4% | $14.85 | $14.92 | $14.41 | 606,500 | |
| $14.92 | +0.09 | +0.6% | $15.01 | $15.31 | $14.63 | 689,608 | |
| $14.83 | +0.49 | +3.4% | $14.28 | $14.94 | $13.72 | 821,374 | |
| $14.34 | -0.20 | -1.4% | $14.70 | $14.85 | $14.10 | 635,500 | |
| $14.54 | -0.43 | -2.9% | $14.93 | $15.01 | $14.50 | 861,900 |
- Ticker
- NASDAQ:MGTX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 16, 2026
MeiraGTx Announces Oral Presentation at ObesityWeek 2026
Latest deck · November 2026
Investor Presentation (November 2026)
Investor deck · 106 slides
Latest news
MeiraGTx Announces Oral Presentation at ObesityWeek 2026
Nov 16, 2026
Closed $8.74 (-4.8%) on Nov 16, 2026
MeiraGTx Reports Third Quarter 2026 Financial and Operational Results
Nov 12, 2026
Closed $8.79 (-9.2%) on Nov 12, 2026
MeiraGTx Announces Four Posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and the Network of Excellence for ALS (NEALS) Annual Meeting
Oct 27, 2026
Closed $9.40 (+2.4%) on Oct 27, 2026
MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors
Sep 23, 2026
Closed $11.75 (-4.9%) on Sep 23, 2026
MeiraGTx Reports Second Quarter 2026 Financial and Operational Results
Aug 13, 2026
Closed $12.67 (-2.2%) on Aug 13, 2026
MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)
Jul 7, 2026
Closed $14.66 (+5.5%) on Jul 7, 2026
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 14, 2026
Closed $9.40 (-5.5%) on May 15, 2026
Company announcement: amendment notice
Apr 20, 2026
Closed $10.17 (-3.4%) on Apr 21, 2026
MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares
Apr 16, 2026
Closed $9.48 (-15.7%) on Apr 16, 2026
MeiraGTx Holdings plc on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 15 in the last 12 months · 107 in all · newest Nov 16, 2026 · oldest 2019
- Decks
- 12 decks · latest November 2026
Where MeiraGTx Holdings plc is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:MGTX · Home listing · This page | NASDAQ | United States | USD |
| gettex:328 | gettex | Germany | EUR |
| LS Exchange:A2JGHF | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2JGHF | Lang & Schwarz | Germany | EUR |
| BOATS:MGTX | BOATS | United States | USD |
| Tradegate:328 | Tradegate | Germany | EUR |
| Frankfurt:328 | Frankfurt | Germany | EUR |
| Munich:328 | Munich | Germany | EUR |
| Stuttgart:328 | Stuttgart | Germany | EUR |
Valuation
P/E 9.8× against a median of 4.4×: 4th lowest of 5 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $715.6M USD
- P/E
- 9.8×
- EV/sales
- 1.8×
- EV/EBITDA
- 3.7×
- Price/book
- 3.6×
- Gross margin
- 83.7%
- Operating margin
- 44.8%
- Net margin
- 19.5%
- Debt to equity
- 0.6×
- Beta vs S&P 500
- 1.57
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| MeiraGTx Holdings plc · NASDAQ:MGTX | US$766.4M | US$715.6M | 9.8× | 1.8× | 3.7× | 3.6× | 19.5% | 0.6× | 1.57 |
| Arbutus Biopharma Corporation · NASDAQ:ABUS | US$796.4M | US$458.9M | 3.6× | 2.5× | 3.1× | 9.3× | 121.2% | 0.0× | 1.10 |
| Genfleet Therapeutics (Shanghai), Inc. Class H · HKEX:2595 | US$787.6M | US$518.9M | n/a | 26.5× | n/a | 3.3× | n/a | 0.0× | n/a |
| Shaanxi Micot Pharmaceutical Technology Co., Ltd. Class H · HKEX:2335 | US$778.8M | US$599.7M | n/a | n/a | n/a | 5.5× | n/a | 0.0× | n/a |
| Ironwood Pharmaceuticals, Inc. · NASDAQ:IRWD | US$778.1M | US$702.9M | 5.2× | 1.8× | n/a | n/a | 37.4% | n/a | 1.16 |
| Syndax Pharmaceuticals, Inc. · NASDAQ:SNDX | US$772.7M | US$695.6M | n/a | 2.4× | n/a | n/a | −72.4% | n/a | 0.64 |
| ORIC Pharmaceuticals, Inc. · NASDAQ:ORIC | US$764.9M | US$503.6M | n/a | n/a | n/a | 2.3× | n/a | 0.0× | 1.22 |
| Inventiva SA · EURONEXT:IVA | US$761.0M | US$577.4M | n/a | 117× | n/a | 11.8× | n/a | 1.1× | n/a |
| Rigel Pharmaceuticals, Inc. · NASDAQ:RIGL | US$754.9M | US$663.4M | 2.5× | 2.3× | 8.3× | 1.7× | 106.6% | 0.0× | 1.02 |
| Obsidian Therapeutics, Inc. · NASDAQ:OBX | US$741.3M | US$530.4M | 13.0× | n/a | n/a | 2.3× | n/a | 0.0× | n/a |
| Monte Rosa Therapeutics, Inc. · NASDAQ:GLUE | US$738.3M | US$196.8M | n/a | 2.8× | n/a | 1.5× | −186.2% | 0.1× | 0.92 |
| Median of the others | US$768.8M | US$553.9M | 4.4× | 2.5× | 5.7× | 2.8× | 37.4% | 0.0× | 1.06 |
Forecasts
5 strong buy · 2 buy · 1 hold · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 27.75 USD · Analysts' mean
- EPS, year to Dec 2026
- 0.51 · 3 analysts
- Revenue, year to Dec 2026
- 333.3M · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Alexandria Forbes | Board Member, President and Chief Executive Officer |
Board
| Director | Role |
|---|---|
| Keith R. Harris | Chairman of the Board |
| Alan Sebulsky | Independent Board Member |
| Alexandria Forbes | Board Member, President and Chief Executive Officer |
| Debra Yu | Independent Board Member |
| Ellen Hukkelhoven | Board Member |
| Nicole Seligman | Independent Board Member |
| Thomas E. Shenk | Independent Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · Before open | −9.2% |
| Q2 2026 | Aug 13, 2026 · Before open | −2.2% |
| Q1 2026 | May 14, 2026 · Before open | −0.2% |
| Q4 2025 | Mar 12, 2026 | −5.4% |
| Q3 2025 | Nov 13, 2025 · Before open | −4.6% |
| Q2 2025 | Aug 14, 2025 · Before open | −0.1% |
| Q1 2025 | May 13, 2025 · Before open | −8.4% |
| Q4 2024 | Mar 12, 2025 · Before open | +5.1% |
| Q3 2024 | Nov 13, 2024 · Before open | +5.7% |
| Q2 2024 | Aug 12, 2024 · Before open | −8.5% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · Before open | −0.8% |
| Q4 2023 | Mar 14, 2024 · Before open | −7.1% |
| Q3 2023 | Nov 14, 2023 · Before open | +2.3% |
| Q2 2023 | Aug 10, 2023 · Before open | +4.3% |
| Q1 2023 | May 11, 2023 · Before open | −6.0% |
| Q4 2022 | Mar 14, 2023 · Before open | +1.8% |
| Q3 2022 | Nov 10, 2022 · After close | −3.7% |
| Q2 2022 | Aug 11, 2022 · Before open | +6.7% |
| Q1 2022 | May 12, 2022 · Before open | +0.3% |
| Q4 2021 | Mar 10, 2022 · Before open | +0.5% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 106 slides | November 2026 |
| Investor Presentation (October 2026) | Investor deck | 24 slides | October 2026 |
| Investor Presentation (October 2026) | Investor deck | 97 slides | October 2026 |
| Investor Presentation (October 2026) | Investor deck | 13 slides | October 2026 |
| Investor Presentation (August 2026) | Investor deck | 97 slides | August 2026 |
| Foundation Fighting Blindness (FFB) Retinal Therapeutics Innovation Summit 2025 | Conference | 14 slides | May 2, 2025 |
| Technical Presentation (April 2024) | Technical | 16 slides | April 2024 |
| Technical Presentation (June 2023) | Technical | 28 slides | Jun 27, 2023 |
| ARVO Annual Meeting 2023 | Conference | 10 slides | April 2023 |
| ARVO Annual Meeting 2022 | Conference | 13 slides | May 4, 2022 |
All 12 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (December 2021) | Technical | 22 slides | Dec 7, 2021 |
| EURETINA Virtual Meeting 2021 | Conference | 9 slides | Sep 12, 2021 |
Financings
| Raise | Date |
|---|---|
| Public offering of ordinary shares Announced: about US$100M · US$9 a share · BofA Securities +2 Dealers: BofA Securities (co-lead), Goldman Sachs & Co. LLC (co-lead), Raymond James Use of proceeds: Fund operating expenses and capital expenditures, including potential commercial launches of bota-vec and AAV-hAQP1 if approved, into the second half of 2028 | Apr 16, 2026 |
| Strategic investment of minority stake in manufacturing subsidiary Announced: strategic investment Buyers: Hologen Limited (minority stake in MeiraGTx's manufacturing subsidiary) Use of proceeds: Fund a portion of the annual funding of MeiraGTx's manufacturing subsidiary | Mar 13, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$15.00 a share on Jun 7, 2018.
- Price
- US$15.00 a share
- Shares offered
- 5,000,000 ordinary shares
- Offering size
- US$75 million
- Underwriters' option
- Up to 750,000 more shares
- Underwriters
- BofA Merrill Lynch, Barclays, Evercore ISI, Chardan · In the order on the cover
- Shares delivered
- On or about Jun 12, 2018
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Mar 29, 2018 |
| Filed publicly | May 14, 2018 |
| Amended 3 times | Newest Jun 4, 2018 |
| Declared effective by the SEC | Jun 7, 2018 |
| Shares registered with an exchange | Jun 8, 2018 |
| Final prospectus, with the price | Jun 8, 2018 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jun 8, 2018 |
| CERT · Exchange's certificate of listing | Jun 8, 2018 |
| 8-A12B · Registration of shares for listing on an exchange | Jun 8, 2018 |
| EFFECT · Notice that a registration is effective | Jun 7, 2018 |
| CORRESP · Letter to the SEC | Jun 5, 2018 |
| CORRESP · Letter to the SEC | Jun 5, 2018 |
| FWP · Free writing prospectus | Jun 4, 2018 |
| S-1/A · Registration statement, amended | Jun 4, 2018 |
| S-1/A · Registration statement, amended | May 29, 2018 |
| S-1/A · Registration statement, amended | May 23, 2018 |
All 18 filings
| Filing | Filed |
|---|---|
| UPLOAD · Letter from the SEC | May 22, 2018 |
| CORRESP · Letter to the SEC | May 21, 2018 |
| S-1 · Registration statement | May 14, 2018 |
| DRSLTR · Letter to the SEC with a draft | May 11, 2018 |
| DRS/A · Draft registration statement, amended | May 11, 2018 |
| UPLOAD · Letter from the SEC | Apr 26, 2018 |
| DRS/A · Draft registration statement, amended | Apr 13, 2018 |
| DRS · Draft registration statement | Mar 29, 2018 |
Open IPO · From the cover of the final prospectus (424B4) filed Jun 8, 2018
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 81.4M | 33.3M | 14.0M | 15.9M | 37.7M | 15.6M | 13.3M | 0 | 0 | 0 |
| Cost of revenue | 4.84M | 23.8M | 13.7M | 8.72M | 7.87M | 2.05M | 679.2K | 243.1K | ||
| Gross profit | 76.5M | 9.49M | 14.0M | 15.9M | 37.7M | 15.6M | 13.3M | -2.05M | -679.2K | -243.1K |
| Research and development | 129.6M | 119.5M | 103.8M | 85.7M | 66.7M | 33.9M | 24.9M | 33.6M | 22.4M | 14.0M |
| Selling, general and administrative | 52.9M | 54.2M | 47.3M | 46.5M | 43.8M | 44.2M | 46.7M | 44.5M | 9.33M | 6.03M |
| Operating income | -106.0M | -164.2M | -137.1M | -116.4M | -72.8M | -62.6M | -58.3M | -78.1M | -31.7M | -20.1M |
| Depreciation and amortization | 12.5M | 12.8M | 13.7M | 8.72M | 7.87M | 4.17M | 2.24M | 2.05M | 679.2K | 243.1K |
| EBITDA | -93.4M | -151.4M | -123.3M | -107.6M | -64.9M | -58.4M | -56.0M | -76.1M | -31.0M | -19.8M |
| Interest expense | 12.2M | 13.3M | 13.2M | 4.95M | 288.0K | 139.0K | 48.6K | 33.4K | 42.9K | 25.4K |
| Income before tax | -114.2M | -147.8M | -84.0M | -129.6M | -79.6M | -58.0M | -54.7M | -83.3M | -31.0M | -19.8M |
| Income tax | 0 | 0 | 0 | 13.3M | 0 | 0 | 0 | -474.4K | 0 | -280.4K |
| Net income | -114.2M | -147.8M | -84.0M | -129.6M | -79.6M | -58.0M | -54.7M | -82.9M | -31.0M | -19.5M |
| Earnings per share, basic | -1.42 | -2.12 | -1.49 | -2.87 | -1.80 | -1.54 | -1.65 | -4.47 | -3.72 | -1.01 |
| Earnings per share, diluted | -1.42 | -2.12 | -1.49 | -2.87 | -1.80 | -1.54 | -1.65 | -4.47 | -3.72 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 65.9M | 103.7M | 129.6M | 115.5M | 137.7M | 209.5M | 227.2M | 68.1M | 8.55M | 17.5M |
| Receivables | 3.00M | 707.0K | 10.1M | 21.3M | 35.0M | 55.4M | 37.1M | 4.52M | ||
| Inventory | 0 | 385.0K | 0 | 8.13M | 8.10M | 7.08M | 4.46M | |||
| Current assets | 91.8M | 123.5M | 159.6M | 154.3M | 183.2M | 272.6M | 269.0M | 74.7M | 11.5M | 19.1M |
| Property, plant and equipment | 105.5M | 102.9M | 115.9M | 109.3M | 75.9M | 44.0M | 23.9M | 22.0M | 14.3M | 2.81M |
| Total assets | 244.4M | 269.8M | 326.7M | 318.2M | 320.2M | 363.7M | 323.9M | 96.9M | 25.9M | 22.6M |
| Accounts payable | 10.1M | 23.6M | 16.0M | 16.6M | 15.3M | 7.13M | 3.76M | 3.04M | 7.06M | 1.47M |
| Current liabilities | 122.6M | 60.8M | 67.1M | 82.1M | 68.1M | 54.1M | 49.2M | 15.5M | 21.4M | 6.04M |
| Long-term debt | 49.7M | 73.2M | 72.1M | 71.3M | 953.0K | 34.0K | 5.00K | |||
| Total debt | 88.7M | 84.8M | 89.3M | 92.2M | 23.7M | 22.2M | 23.2M | 34.3K | 1.51M | 11.5K |
| Total liabilities | 250.2M | 201.9M | 188.6M | 200.5M | 134.8M | 125.1M | 133.1M | 15.8M | 21.9M | 39.7M |
| Shareholders' equity | -5.79M | 67.8M | 138.2M | 117.7M | 185.4M | 238.6M | 190.8M | 81.1M | -47.4M | -17.1M |
| Shares outstanding | 81.1M | 78.4M | 63.6M | 48.5M | 44.5M | 44.2M | 36.8M | 27.4M | 8.71M | 19.2M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -46.4M | -104.5M | -105.4M | -73.1M | -10.5M | -64.0M | 20.0M | -58.9M | -18.1M | -14.4M |
| Capital spending | -3.83M | -4.96M | -20.2M | -45.0M | -46.4M | -20.9M | -8.98M | -11.3M | -10.5M | -2.59M |
| Free cash flow | -50.2M | -109.5M | -125.5M | -118.1M | -56.9M | -84.9M | 11.1M | -70.1M | -28.6M | -17.0M |
| Cash from investing | -4.11M | 23.5M | 34.0M | -45.0M | -61.7M | -37.0M | -9.37M | -11.3M | -10.5M | -2.59M |
| Cash from financing | 12.3M | 54.5M | 84.0M | 95.2M | 1.71M | 82.7M | 148.2M | 130.0M | 19.3M | 20.8M |
| Dividends paid | 0 | -70.0M | 0 | |||||||
| Share buybacks | -1.52M | -2.77M | 1.71M | 82.8M | 148.3M | 131.5M | 16.9M | 20.8M | ||
| Change in cash | -38.2M | -26.5M | 12.7M | -22.9M | -70.5M | -18.3M | 158.9M | 59.9M | -9.25M | 3.37M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 17, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| S-3ASR · Registration statement | Nov 12, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 20, 2026 | Other filings | SEC |
| 4 · Change in ownership | Oct 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 6, 2026 | Other filings | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Sep 24, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 24, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 23, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 18, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Aug 13, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 21, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 21, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 7, 2026 | Other filings | SEC |
| 8-K · Current report | Jul 7, 2026 | Material contract | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 15, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 19, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 14, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 13, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 30, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 30, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 30, 2026 | Meeting notice | SEC |
| 4/A · Change in ownership, amended | Apr 28, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 24, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Apr 24, 2026 | Material contract | SEC |
| 4 · Change in ownership | Apr 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 21, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 21, 2026 | Other filings | SEC |
| 424B5 · Prospectus | Apr 16, 2026 | Offer document | SEC |
| 8-K · Current report | Apr 16, 2026 | Material contract | SEC |
| 8-K · Current report | Apr 16, 2026 | Acquisition or disposal | SEC |
| 8-K · Current report | Apr 16, 2026 | Current report | SEC |
| 4 · Change in ownership | Apr 7, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 7, 2026 | Other filings | SEC |
| 10-K · Annual report | Mar 30, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 26, 2026 | Results | SEC |
| 4 · Change in ownership | Mar 24, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 24, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 13, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 2, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 2, 2026 | Material contract | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2025 | Results | SEC |
| 8-K · Current report | Nov 10, 2025 | Material contract | SEC |
| 4 · Change in ownership | Oct 21, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 21, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 7, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 7, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2025 | Results | SEC |
| 4 · Change in ownership | Jul 22, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 22, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jul 8, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 8, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 26, 2025 | Current report | SEC |
| 8-K · Current report | Jun 17, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2025 | Results | SEC |
| 8-K · Current report | May 9, 2025 | Current report | SEC |
| ARS · Annual report to shareholders | Apr 30, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 30, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 30, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 22, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 22, 2025 | Other filings | SEC |
| 4 · Change in ownership | Apr 8, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 8, 2025 | Other filings | SEC |
| 4 · Change in ownership | Apr 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 7, 2025 | Insider trade | SEC |
| 8-K · Current report | Apr 4, 2025 | Material contract | SEC |
| S-8 · Registration statement for employee plans | Mar 13, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 13, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 13, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 21, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jan 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 10, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 7, 2025 | Other filings | SEC |
| 8-K · Current report | Dec 9, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Nov 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 18, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Oct 15, 2024 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | Aug 14, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 13, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Aug 13, 2024 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Aug 13, 2024 | Insider trade | SEC |
| 424B5 · Prospectus | Aug 12, 2024 | Offer document | SEC |
| 8-K · Current report | Aug 12, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Jun 10, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2024 | Results | SEC |
| ARS · Annual report to shareholders | Apr 25, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 25, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 25, 2024 | Meeting notice | SEC |
| 8-K/A · Current report, amended | Apr 16, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Apr 8, 2024 | Insider trade | SEC |
| 10-K · Annual report | Mar 15, 2024 | Annual report | SEC |
| 4 · Change in ownership | Mar 14, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 14, 2024 | Results | SEC |
| 4 · Change in ownership | Mar 4, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Feb 13, 2024 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 9, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 7, 2024 | Big-stake notice | SEC |
| 4/A · Change in ownership, amended | Jan 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2024 | Insider trade | SEC |
This page holds 200 of 515 filings. Open Filings
Cap table
Built by 6ix from MeiraGTx Holdings plc’s releases · as of Sep 30, 2026
- Common shares
- 96,042,996
- Fully diluted
- 96,042,996
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 96,042,996 | Sep 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 96,042,996 |
| Sep 30, 2026 | 97,619,453 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Joseph Edelman Other companies: Kardigan, Inc. (Director · Since at least Jun 17, 2026); Immatics N.V. (Director · Since at least Mar 18, 2026); Solid Biosciences Inc. (Director · Since at least Mar 23, 2021); LeonaBio, Inc. (Director · Since at least Sep 17, 2020); Adagio Medical Holdings, Inc (Director · Jan 22, 2025 – Jan 22, 2025 · Past); Freenome, Inc. (Director · Jun 11, 2024 – Jun 11, 2024 · Past); ARYA Sciences Acquisition Corp V (Director · Jul 12, 2021 – Jul 12, 2021 · Past); ARYA Sciences Acquisition IV Corp (Director · Feb 25, 2021 – Jul 31, 2024 · Past); Landos Biopharma Inc (Director · Feb 3, 2021 – Aug 27, 2021 · Past); Astria Therapeutics Inc (Director · Jan 28, 2021 – Feb 1, 2024 · Past); Nautilus Biotechnology, Inc. (Director · Aug 6, 2020 – Jun 14, 2024 · Past); Cerevel Therapeutics Holdings Inc (Director · Jun 4, 2020 – Feb 20, 2024 · Past); Lyra Therapeutics, Inc. (Director · Apr 30, 2020 – May 31, 2023 · Past); ARYA Sciences Acquisition Corp (Director · Oct 5, 2018 – Oct 5, 2018 · Past) | Director · Since at least Nov 23, 2020 |
| Joel S. Marcus Other companies: TRex Bio, Inc. (Director · Since at least Oct 13, 2026); Alexandria Real Estate Equities, Inc. (Executive Chairman & Founder · Since at least May 9, 2007); Korro Bio, Inc. (Director · Oct 2, 2019 – Aug 17, 2022 · Past); Applied Therapeutics Inc (Director · May 13, 2019 – Jun 6, 2024 · Past); Atara Biotherapeutics, Inc. (Director · Oct 15, 2014 – Mar 15, 2019 · Past); Intra-Cellular Therapies Inc (Director · Sep 9, 2013 – Apr 2, 2025 · Past); Rexford Industrial Realty, Inc. (Director · Jul 18, 2013 – May 30, 2014 · Past); PennyMac Mortgage Investment Trust (Director · Aug 4, 2009 – May 16, 2012 · Past) | Director · Jun 8, 2018 – Jun 7, 2022 · Past |
| Nicole Seligman Other companies: Praetorian Acquisition Corp. (Director · Since at least Jan 22, 2026); Intuitive Machines, Inc. (Director · Since at least Jun 23, 2023); Far Peak Acquisition Corp (Director · Dec 2, 2020 – Dec 2, 2020 · Past); ViacomCBS Inc (Director · Dec 4, 2019 – May 8, 2024 · Past); Far Point Acquisition Corporation (Director · Jun 11, 2018 – Aug 28, 2020 · Past); Viacom Inc (Director · Aug 18, 2016 – Dec 4, 2019 · Past) | Independent Board Member · Since at least May 9, 2019 |
| Alan Sebulsky Other companies: Parabilis Medicines, Inc. (President, Apothecary Capital Management, Inc · Since at least Jun 9, 2026); Jazz Pharmaceuticals plc (Director · May 31, 2007 – Mar 9, 2012 · Past); Arrow International Inc (Director · Jan 18, 2006 – Oct 1, 2007 · Past) | Independent Board Member · Since at least Sep 23, 2026 |
| Arnold J Levine Other companies: PMV Pharmaceuticals, Inc. (Director · Since at least Sep 24, 2020); Applied Biosystems Inc. (Director · Mar 1, 2006 – Nov 21, 2008 · Past); Innoviva, Inc. (Director · Dec 31, 2005 – Mar 21, 2014 · Past) | Director · Jun 8, 2018 – Jun 7, 2022 · Past |
| Gregory S. Moss Other companies: Evommune, Inc. (Chief Business and Legal Officer · Since at least Nov 5, 2025); Anteris Technologies Global Corp. (Director · Since at least Jun 7, 2025); Kadmon Holdings Inc (EVP, Gen. Coun. / CCO. · Aug 30, 2019 – Nov 9, 2021 · Past) | Director · Jun 8, 2018 – Jun 8, 2018 · Past |
| Debra Yu Other companies: Ascentage Pharma Group International (Independent non-executive Director · Since at least Mar 18, 2026); ARYA Sciences Acquisition Corp V (Director · Jul 12, 2021 – Jul 12, 2021 · Past) | Independent Board Member · Since at least Apr 25, 2022 |
| Robert K Zeldin Other companies: Immunovant, Inc. (Chief Medical Officer · Dec 18, 2019 – Dec 18, 2019 · Past); Acceleron Pharma Inc (EVP & Chief Medical Officer · Jun 29, 2018 – Jan 25, 2019 · Past) | CHIEF MEDICAL OFFICER · Since at least Aug 3, 2020 |
| Thomas E. Shenk Other companies: Kadmon Holdings Inc (Director · Jul 26, 2016 – Jun 29, 2017 · Past); Vical Incorporated (Director · Dec 18, 2015 – May 23, 2018 · Past) | Independent Board Member · Since at least Jun 8, 2018 |
| Alexandria Forbes Other companies: Kadmon Holdings Inc (Director · Jul 26, 2016 – Jun 29, 2017 · Past) | Board Member, President and Chief Executive Officer · Since at least Jun 8, 2018 |
All 20 people
| Person | Seat |
|---|---|
| Keith R. Harris Other companies: vTv Therapeutics Inc. (Director · Jul 11, 2022 – Jun 19, 2023 · Past) | Chairman of the Board · Since at least Jun 8, 2018 |
| Richard Giroux Other companies: Chardan Healthcare Acquisition 2 Corp (Director · Apr 23, 2020 – Apr 23, 2020 · Past) | CFO & COO · Since at least Jun 8, 2018 |
| Bruce Gottlieb | General Counsel · Apr 1, 2019 – Apr 1, 2019 · Past |
| Ellen Hukkelhoven | Board Member · Since at least Jun 8, 2018 |
| Katherine Breedis | Chief Financial Officer · Oct 2, 2018 – Dec 29, 2018 · Past |
| Martin Indyk | Director · Feb 19, 2019 – Jun 5, 2024 · Past |
| Neil Mendoza | Director · Since at least Jun 8, 2018 |
| Penny Renee Fleck | CHIEF DEVELOPMENT OFFICER · Since at least May 11, 2026 |
| Robert J Wollin | GENERAL COUNSEL AND SECRETARY · Since at least Jun 10, 2020 |
| Stuart Naylor | CHIEF SCI OFCR, OPHTHALMOLOGY · Since at least Jun 8, 2018 |
Log in to ask 6ix AI your own questions about MeiraGTx Holdings plc.